Cited by 72SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing

Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)

Open access
Jiang, Chuanhao, Wang, Yali, Hu, Min, Wen, Lingjun, Wen, Chuan, Wang, Yang, Zhu, Weihong, Tai, Shi +6 more·2020·Clinical & Translational Immunology

Abstract

Objectives: Asymptomatic and symptomatic patients may transmit severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), but their clinical features and immune responses remain largely unclear. We aimed to characterise the clinical features and immune responses of asymptomatic and symptomatic patients infected with SARS‐CoV‐2. Methods: We collected clinical, laboratory and epidemiological records of patients hospitalised in a coronavirus field hospital in Wuhan. We performed qualitative detection of anti‐SARS‐CoV‐2 immunoglobulin M (IgM) and immunoglobulin G (IgG) using archived blood samples. Results: Of 214 patients with SARS‐CoV‐2, 26 (12%) were asymptomatic at hospital admission and during hospitalisation. Most asymptomatic patients were ≤ 60 years (96%) and females (65%) and had few comorbidities (< 16%). Serum levels of white and red blood cells were higher in asymptomatic than in symptomatic patients (P‐values < 0.05). During hospitalisation, IgG seroconversion was commonly observed in both asymptomatic and symptomatic patients (85% versus 94%, P‐value = 0.07); in contrast, IgM seroconversion was less common in asymptomatic than in symptomatic patients (31% versus 74%, P‐value < 0.001). The median time from the first virus‐positive screening to IgG or IgM seroconversion was significantly shorter in asymptomatic than in symptomatic patients (median: 7 versus 14 days, P‐value < 0.01). Furthermore, IgG/IgM seroconversion rates increased concomitantly with the clearance of SARS‐CoV‐2 in both asymptomatic and symptomatic patients. At the time of virus clearance, IgG/IgM titres and plasma neutralisation capacity were significantly lower in recovered asymptomatic than in recovered symptomatic patients (P‐values < 0.01). Conclusion: Asymptomatic and symptomatic patients exhibited different kinetics of IgG/IgM responses to SARS‐CoV‐2. Asymptomatic patients may transmit SARS‐CoV‐2, highlighting the importance of early diagnosis and treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cti2.1182

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jiang, C., Wang, Y., Hu, M., Wen, L., Wen, C., Wang, Y., Zhu, W., Tai, S., Jiang, Z., Xiao, K., Faria, N. R., De Clercq, E., Xu, J., & Li, G.
Affiliations
  • Second Xiangya Hospital of Central South University (CN)
  • Central South University (CN)
  • University of Oxford (GB)
  • Department of Microbiology, Immunology and Transplantation Rega Institute for Medical Research KU Leuven Leuven Belgium
Corresponding author
Li, Guangdi
Venue
Clinical & Translational Immunology
Publisher
Wiley
Published
2020-01
Volume
9
Issue
9
Pages
e1182-e1182
ISSN
2050-0068 (ISSN-L)
OpenAlex
W3088609705
Cited by
72
References
1
Citations by year
2025: 1 · 2024: 6 · 2023: 8 · 2022: 22 · 2021: 32 · 2020: 3
FWCI
2.13
Type
journal article
Language
en
Open access
Locations
  • Clinical & Translational Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (2018ZX10715004, 31571368, 81701577, 81730064, 2018RS3006, 31871324)
  • National Science and Technology Major Project (2018ZX10715004)
  • Medical Research Council (MR/R015600/1, MR/S019510/1, MC_PC_19012)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords
SARS-CoV-2, COVID-19 pandemic, asymptomatic infection, symptomatic infection, antibody seroconversion, IgM, IgG, neutralizing antibodies, immune response kinetics, viral clearance, blood cell count

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review